INCB18424
Showing 1 - 25 of 82
T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Ruxolitinib)
Not yet recruiting
- T-Cell Large Granular Lymphocyte Leukemia
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 20, 2022
Myelofibrosis Trial in Houston (Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib)
Active, not recruiting
- Myelofibrosis
- Long-term Follow-up
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 7, 2022
Hematopoietic and Lymphoid Cell Tumor, Steroid Refractory GVHD Trial in Houston (Cellular Therapy, Ruxolitinib)
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- Steroid Refractory Graft Versus Host Disease
- Cellular Therapy
- Ruxolitinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Active, not recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +2 more
-
Columbus, Ohio
- +2 more
Aug 10, 2022
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of
Recruiting
- BCR-JAK2 Fusion Protein Expression
- +11 more
-
Palo Alto, California
- +3 more
Oct 5, 2022
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,
Recruiting
- Acute Myeloid Leukemia
- +8 more
- Decitabine
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 18, 2022
Atopic Dermatitis (AD) Trial (Ruxolitinib Cream)
Not yet recruiting
- Atopic Dermatitis (AD)
- Ruxolitinib Cream
- (no location specified)
Jul 8, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Duarte (procedure, drug, other)
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 2, 2021
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +11 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in
Active, not recruiting
- Metastatic Malignant Neoplasm in the Bone
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 4, 2023
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)
Recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 21, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia Trial in Houston (Ruxolitinib,
Completed
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Untreated Chronic Lymphocytic Leukemia
- Ruxolitinib
- Ruxolitinib Phosphate
-
Houston, TexasM D Anderson Cancer Center
Mar 23, 2021
Chronic Lymphocytic Leukemia Trial in Houston (Questionnaire Administration, Ruxolitinib Phosphate)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Questionnaire Administration
- Ruxolitinib Phosphate
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,
Completed
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual
Terminated
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +3 more
- Dasatinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 1, 2020
Recurrent Breast Cancer, Metastatic Breast Cancer Trial in Boston (Ruxolitinib, Paclitaxel)
Completed
- Recurrent Breast Cancer
- Metastatic Breast Cancer
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 26, 2021
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (Biospecimen Collection, Chest
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- Biospecimen Collection
- +7 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 9, 2023
Recurrent DLBCL, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Bethesda, Rochester, Omaha
Completed
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- Ruxolitinib Phosphate
-
Bethesda, Maryland
- +2 more
Jul 7, 2021
Chronic Hand Eczema (CHE) Trial in Worldwide (Ruxolitinib cream, Vehicle)
Withdrawn
- Chronic Hand Eczema (CHE)
- Ruxolitinib cream
- Vehicle
-
Birmingham, Alabama
- +38 more
Nov 7, 2022
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in
Recruiting
- Myelodysplastic Syndrome
- +16 more
- Computed Tomography
- +6 more
-
Scottsdale, Arizona
- +2 more
Feb 3, 2022
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia Trial in United States (Laboratory Biomarker
Completed
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Chronic Neutrophilic Leukemia
- Laboratory Biomarker Analysis
- +3 more
-
Palo Alto, California
- +6 more
Oct 22, 2020
Prurigo Nodularis Trial (Ruxolitinib Cream, Vehicle Cream)
Not yet recruiting
- Prurigo Nodularis
- Ruxolitinib Cream
- Vehicle Cream
- (no location specified)
Mar 1, 2023